Depicting the landscape of gut microbial-metabolic interaction and microbial-host immune heterogeneity in deficient and proficient DNA mismatch repair colorectal cancers
暂无分享,去创建一个
Xinxiang Li | Yongzhi Yang | L. Du | Jianqiang Liu | Jinming Li | Yanlei Ma | Fanying Guo | Yangyang Guo | Lutao Du
[1] S. Bullman,et al. Effect of the intratumoral microbiota on spatial and cellular heterogeneity in cancer , 2022, Nature.
[2] M. Blaser,et al. Tumor microbiome links cellular programs and immunity in pancreatic cancer. , 2022, Cancer cell.
[3] Xinxiang Li,et al. Integrated metagenomic and metabolomic analysis reveals distinct gut-microbiome-derived phenotypes in early-onset colorectal cancer , 2022, Gut.
[4] H. Vlamakis,et al. Akkermansia muciniphila phospholipid induces homeostatic immune responses , 2022, Nature.
[5] Liang Zhou,et al. Fusobacterium nucleatum impairs DNA mismatch repair and stability in patients with squamous cell carcinoma of the head and neck , 2022, Cancer.
[6] M. Gonen,et al. PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer. , 2022, The New England journal of medicine.
[7] F. Sinicrope,et al. Mismatch Repair-Deficient Colorectal Cancer: Building on Checkpoint Blockade. , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] W. D. de Vos,et al. Akkermansia muciniphila: paradigm for next-generation beneficial microorganisms , 2022, Nature Reviews Gastroenterology & Hepatology.
[9] Hongzhong Li,et al. Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies , 2022, Journal of Hematology & Oncology.
[10] J. Badger,et al. Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1 , 2022, Nature Medicine.
[11] T. Spector,et al. Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma , 2022, Nature Medicine.
[12] N. Segata,et al. Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer , 2022, Nature Medicine.
[13] D. Hanahan. Hallmarks of Cancer: New Dimensions. , 2022, Cancer discovery.
[14] M. Tsuboi,et al. Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments. , 2022, Cancer cell.
[15] M. Kloor,et al. The different immune profiles of normal colonic mucosa in cancer-free Lynch syndrome carriers and Lynch syndrome colorectal cancer patients. , 2021, Gastroenterology.
[16] H. Qin,et al. Fusobacterium nucleatum enhances the efficacy of PD-L1 blockade in colorectal cancer , 2021, Signal Transduction and Targeted Therapy.
[17] R. Rodrigues,et al. Microbiota triggers STING-type I IFN-dependent monocyte reprogramming of the tumor microenvironment , 2021, Cell.
[18] W. Yuan,et al. Interaction between intestinal microbiota and tumour immunity in the tumour microenvironment , 2021, Immunology.
[19] M. Sawyer,et al. Nivolumab + low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.
[20] J. Badger,et al. Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients , 2021, Science.
[21] Yang Gu,et al. Discovery of an ene-reductase for initiating flavone and flavonol catabolism in gut bacteria , 2021, Nature communications.
[22] Timothy L. Tickle,et al. Multivariable association discovery in population-scale meta-omics studies , 2021, bioRxiv.
[23] Pengxian Tao,et al. Effects of Antibiotic Use on Outcomes in Cancer Patients Treated Using Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. , 2020, Journal of immunotherapy.
[24] M. Kloor,et al. The shared frameshift mutation landscape of microsatellite-unstable cancers suggests immunoediting during tumor evolution , 2020, Nature Communications.
[25] E. Allen-Vercoe,et al. A Microbiota-Derived Metabolite Augments Cancer Immunotherapy Responses in Mice. , 2020, Cancer cell.
[26] Ping-Chih Ho,et al. Lactate modulation of immune responses in inflammatory versus tumour microenvironments , 2020, Nature Reviews Immunology.
[27] Michelle L. Reyzer,et al. Accumulation of long-chain fatty acids in the tumor microenvironment drives dysfunction in intrapancreatic CD8+ T cells , 2020, The Journal of experimental medicine.
[28] A. Broeks,et al. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers , 2020, Nature Medicine.
[29] A. Jemal,et al. Colorectal cancer statistics, 2020 , 2020, CA: a cancer journal for clinicians.
[30] I. Asangani,et al. Tumor-Derived Retinoic Acid Regulates Intratumoral Monocyte Differentiation to Promote Immune Suppression , 2020, Cell.
[31] M. Scholz,et al. Propionic Acid Shapes the Multiple Sclerosis Disease Course by an Immunomodulatory Mechanism , 2020, Cell.
[32] Rob Knight,et al. Microbiome analyses of blood and tissues suggest cancer diagnostic approach , 2020, Nature.
[33] L. Ivashkiv. The hypoxia–lactate axis tempers inflammation , 2019, Nature Reviews Immunology.
[34] K. Kogure,et al. Biological Functions of α-Tocopheryl Succinate. , 2019, Journal of nutritional science and vitaminology.
[35] L. Zitvogel,et al. The negative impact of antibiotics on outcomes in cancer patients treated with immunotherapy: a new independent prognostic factor? , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.
[36] Steven L Salzberg,et al. Graph-based genome alignment and genotyping with HISAT2 and HISAT-genotype , 2019, Nature Biotechnology.
[37] Jun Yu,et al. Peptostreptococcus anaerobius promotes colorectal carcinogenesis and modulates tumour immunity , 2019, Nature Microbiology.
[38] E. Giovannucci,et al. Global burden of colorectal cancer: emerging trends, risk factors and prevention strategies , 2019, Nature Reviews Gastroenterology & Hepatology.
[39] D. Plichta,et al. Akkermansia muciniphila induces intestinal adaptive immune responses during homeostasis , 2019, Science.
[40] Ash A. Alizadeh,et al. Determining cell-type abundance and expression from bulk tissues with digital cytometry , 2019, Nature Biotechnology.
[41] A. Goel,et al. DNA Mismatch Repair Deficiency and Immune Checkpoint Inhibitors in Gastrointestinal Cancers. , 2019, Gastroenterology.
[42] Namrata Iyer,et al. Commensals Suppress Intestinal Epithelial Cell Retinoic Acid Synthesis to Regulate Interleukin‐22 Activity and Prevent Microbial Dysbiosis , 2018, Immunity.
[43] Casey M. Theriot,et al. Gut microbiome–mediated bile acid metabolism regulates liver cancer via NKT cells , 2018, Science.
[44] J. Slotta-Huspenina,et al. Gut microbiota modulate T cell trafficking into human colorectal cancer , 2018, Gut.
[45] M. Sawyer,et al. Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[46] Laurence Zitvogel,et al. Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors , 2018, Science.
[47] Riyue Bao,et al. The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patients , 2018, Science.
[48] Ludmila V. Danilova,et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade , 2017, Science.
[49] Fangfang Guo,et al. Fusobacterium nucleatum Promotes Chemoresistance to Colorectal Cancer by Modulating Autophagy , 2017, Cell.
[50] D. Wallace,et al. Foxp3 Reprograms T Cell Metabolism to Function in Low-Glucose, High-Lactate Environments. , 2017, Cell metabolism.
[51] A. Eggermont,et al. Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[52] N. Bhattacharya,et al. Normalizing Microbiota-Induced Retinoic Acid Deficiency Stimulates Protective CD8(+) T Cell-Mediated Immunity in Colorectal Cancer. , 2016, Immunity.
[53] J. Rathmell,et al. A guide to immunometabolism for immunologists , 2016, Nature Reviews Immunology.
[54] F. Bäckhed,et al. From Dietary Fiber to Host Physiology: Short-Chain Fatty Acids as Key Bacterial Metabolites , 2016, Cell.
[55] M. Kloor,et al. The Immune Biology of Microsatellite-Unstable Cancer. , 2016, Trends in cancer.
[56] F. Ginhoux,et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota , 2015, Science.
[57] Mingyang Song,et al. Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis , 2015, Gut.
[58] B. Vogelstein,et al. PD-1 blockade in tumors with mismatch repair deficiency. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[59] Christopher D. Heinen,et al. Milestones of Lynch syndrome: 1895–2015 , 2015, Nature Reviews Cancer.
[60] M. Meyerson,et al. Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. , 2013, Cell host & microbe.
[61] Wei Li,et al. RSeQC: quality control of RNA-seq experiments , 2012, Bioinform..
[62] D. Kominsky,et al. Retinoic acid attenuates ileitis by restoring the balance between T-helper 17 and T regulatory cells. , 2011, Gastroenterology.
[63] S. Gruber,et al. Microsatellite instability in colorectal cancer—the stable evidence , 2010, Nature Reviews Clinical Oncology.
[64] Davis J. McCarthy,et al. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data , 2009, Bioinform..
[65] J. Jiricny. The multifaceted mismatch-repair system , 2006, Nature Reviews Molecular Cell Biology.
[66] K. Kinzler,et al. The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints , 2015, Journal of Immunotherapy for Cancer.